BioCryst Pharmaceuticals (NASDAQ:BCRX) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Profitability
This table compares BioCryst Pharmaceuticals and Athira Pharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
BioCryst Pharmaceuticals | -233.45% | -328.70% | -71.11% |
Athira Pharma | N/A | N/A | N/A |
Valuation & Earnings
This table compares BioCryst Pharmaceuticals and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
BioCryst Pharmaceuticals | $48.83 million | 39.70 | $-108,900,000.00 | ($0.94) | -11.62 |
Athira Pharma | N/A | N/A | $-5,160,000.00 | N/A | N/A |
Athira Pharma has lower revenue, but higher earnings than BioCryst Pharmaceuticals.
Analyst Recommendations
This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Athira Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
BioCryst Pharmaceuticals | 0 | 3 | 8 | 0 | 2.73 |
Athira Pharma | 0 | 0 | 4 | 0 | 3.00 |
BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Athira Pharma has a consensus target price of $42.50, suggesting a potential upside of 120.32%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than BioCryst Pharmaceuticals.
Insider & Institutional Ownership
72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Athira Pharma beats BioCryst Pharmaceuticals on 6 of the 10 factors compared between the two stocks.